Compare CSTL & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | TCMD |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.1M | 533.5M |
| IPO Year | 2019 | 2016 |
| Metric | CSTL | TCMD |
|---|---|---|
| Price | $21.16 | $24.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $45.50 | $36.00 |
| AVG Volume (30 Days) | ★ 468.8K | 335.9K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | $11.60 |
| Revenue Next Year | $12.69 | $9.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $9.42 |
| 52 Week High | $44.28 | $37.77 |
| Indicator | CSTL | TCMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 49.25 |
| Support Level | $17.72 | $22.78 |
| Resistance Level | $24.46 | $27.19 |
| Average True Range (ATR) | 1.12 | 1.01 |
| MACD | 0.37 | 0.18 |
| Stochastic Oscillator | 74.65 | 55.81 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.